• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌预防试验(PCPT)的实施。

Implementation of the Prostate Cancer Prevention Trial (PCPT).

作者信息

Goodman Phyllis J, Tangen Catherine M, Crowley John J, Carlin Susan M, Ryan Anne, Coltman Charles A, Ford Leslie G, Thompson Ian M

机构信息

Southwest Oncology Group Statistical Center, M/S M3-C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109-1024, USA.

出版信息

Control Clin Trials. 2004 Apr;25(2):203-22. doi: 10.1016/j.cct.2003.11.007.

DOI:10.1016/j.cct.2003.11.007
PMID:15020037
Abstract

The Prostate Cancer Prevention Trial is a randomized double blind chemoprevention trial of 18,882 men. It is designed to test the difference in the histologically proven prostate cancer prevalence between a group of participants given finasteride and another given placebo for 7 years. We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase.

摘要

前列腺癌预防试验是一项针对18882名男性的随机双盲化学预防试验。该试验旨在测试服用非那雄胺的一组参与者与服用安慰剂7年的另一组参与者在组织学确诊的前列腺癌患病率上的差异。我们概述了研究设计、研究管理结构的细节以及入组阶段成功实施的描述。

相似文献

1
Implementation of the Prostate Cancer Prevention Trial (PCPT).前列腺癌预防试验(PCPT)的实施。
Control Clin Trials. 2004 Apr;25(2):203-22. doi: 10.1016/j.cct.2003.11.007.
2
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.前列腺癌预防试验中男性报告的性功能纵向分析。
J Natl Cancer Inst. 2007 Jul 4;99(13):1025-35. doi: 10.1093/jnci/djm023. Epub 2007 Jun 27.
3
[The PCPT trial].[前列腺癌预防试验]
Prog Urol. 2008 Apr;18 Suppl 3:S40-3. doi: 10.1016/S1166-7087(08)70512-8.
4
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.5α-还原酶抑制剂对前列腺癌自然病程、检测及分级的影响:当前知识现状
J Urol. 2005 Dec;174(6):2098-104. doi: 10.1097/01.ju.0000181216.71605.38.
5
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.前列腺癌预防试验的启示:生存结果的决策分析模型
J Clin Oncol. 2005 Mar 20;23(9):1911-20. doi: 10.1200/JCO.2005.03.137.
6
Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.非那雄胺作为前列腺癌的化学预防剂:前列腺癌预防试验对泌尿外科实践的影响
Nat Clin Pract Urol. 2006 Aug;3(8):422-9. doi: 10.1038/ncpuro0574.
7
Prostate cancer: a serious disease suitable for prevention.前列腺癌:一种适合预防的严重疾病。
BJU Int. 2009 Apr;103(7):864-70. doi: 10.1111/j.1464-410X.2008.08206.x.
8
The cost of prostate cancer chemoprevention: a decision analysis model.前列腺癌化学预防的成本:一种决策分析模型。
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221.
9
The finasteride prostate cancer prevention trial (PCPT)--what have we learned?非那雄胺前列腺癌预防试验(PCPT)——我们学到了什么?
Eur J Cancer. 2005 Sep;41(13):2016-22. doi: 10.1016/j.ejca.2005.06.010.
10
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.非那雄胺对前列腺体积影响所致的检测偏倚:前列腺癌预防试验分析的一种建模方法
J Natl Cancer Inst. 2007 Sep 19;99(18):1366-74. doi: 10.1093/jnci/djm130. Epub 2007 Sep 11.

引用本文的文献

1
Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI.前列腺活检推荐和接受的差异使前列腺癌危险因素的评估变得复杂:研究种族和 BMI。
Cancer Epidemiol. 2019 Dec;63:101619. doi: 10.1016/j.canep.2019.101619. Epub 2019 Oct 19.
2
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.前列腺活检推荐和接受过程中的偏差显著影响前列腺癌风险因素评估:两项大型随机临床试验的结果
J Clin Oncol. 2016 Dec 20;34(36):4338-4344. doi: 10.1200/JCO.2016.68.1965. Epub 2016 Oct 28.
3
Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.
美国国立癌症研究所资助的社区临床肿瘤计划中癌症预防临床试验的数据和标本的持续使用。
Semin Oncol. 2015 Oct;42(5):748-63. doi: 10.1053/j.seminoncol.2015.07.006. Epub 2015 Jul 10.
4
Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.前列腺癌预防试验安慰剂组中人类疱疹病毒8型血清状态与前列腺癌风险的前瞻性研究。
Cancer Causes Control. 2015 Jan;26(1):35-44. doi: 10.1007/s10552-014-0480-5. Epub 2014 Oct 31.
5
Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).与研究结束时活检依从性相关的因素:来自前列腺癌预防试验(SWOG 协调的多中心研究 S9217)的经验教训。
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202. Epub 2014 Jul 15.
6
Statin drug use is not associated with prostate cancer risk in men who are regularly screened.定期筛查的男性中,他汀类药物的使用与前列腺癌风险无关。
J Urol. 2014 Aug;192(2):379-84. doi: 10.1016/j.juro.2014.01.095. Epub 2014 Feb 8.
7
A perspective on the role of estrogen in hormone-induced prostate carcinogenesis.雌激素在激素诱导的前列腺癌发生中作用的观点。
Cancer Lett. 2013 Jun 28;334(1):28-33. doi: 10.1016/j.canlet.2012.08.027. Epub 2012 Aug 29.
8
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.前瞻性研究巨细胞病毒血清状态与前列腺癌预防试验中的前列腺癌风险。
Cancer Causes Control. 2012 Sep;23(9):1511-8. doi: 10.1007/s10552-012-0028-5. Epub 2012 Jul 19.
9
Hormones and prostate carcinogenesis: Androgens and estrogens.激素与前列腺癌发生:雄激素与雌激素。
J Carcinog. 2011;10:33. doi: 10.4103/1477-3163.90678. Epub 2011 Dec 8.
10
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.前列腺癌的化学预防:天然化合物、抗雄激素和抗氧化剂——体内证据。
J Carcinog. 2011;10:27. doi: 10.4103/1477-3163.90438. Epub 2011 Nov 30.